Quick Hits

Vedolizumab (Entyvio, Takeda Pharmaceuticals America, Deerfield, IL) is a humanized monoclonal antibody to α-4 β-7 integrin, which is expressed on lymphocytes and is the ligand to mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), preferentially expressed on endothelial cells in the gut vasculature. Vedolizumab selectively interferes with lymphocyte homing in the gut, thus affording the potential […]

Quick Hits

Physicians who care for patients with inflammatory bowel disease (IBD) must be aware of the unique health maintenance issues facing these patients in order to deliver appropriate medical care.1 Studies have shown that patients with IBD do not receive routine preventive care at the same rate as patients with other medical conditions.2 Recent data also […]

Quick Hits

In the realm of inflammatory bowel disease (IBD), endpoints can be based on many things. We commonly use subjective assessments and complement these with more objective evaluations, including laboratory, endoscopic and radiologic studies. A great deal depends on the context in which these are considered: are they in reference to an individual patient or to […]

Quick Hits

The pathogenesis of IBD is complex and involves both genetic and environmental factors. Among the environmental factors associated with IBD, diet and the intestinal microbiota would seem the most likely to be modifiable, making them potential targets for disease prevention and treatment. Also, in the past five years, researchers have learned much about the effects […]